A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been ...

Southwest United Graduate School, Yunnan Key Laboratory of Cell Metabolism and Diseases, State Key Laboratory of Conservation and Utilization of Bio-resources in Yunnan Center for Life Sciences, ...

Dr Anne Peters discusses how to safely prescribe SGLT2 inhibitors in patients with type 1 diabetes to prevent diabetic ketoacidosis.

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have ...

How Genetic Factors Are Associated with Behavioral Side Effects of GLP-1 Weight Loss Medication Glucagon-like peptide 1 ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

Our mission is to provide a state-of-the-art facility, expertise, and education in advanced quantitative light microscopy to support Drexel University’s research community The Cell Imaging Center (CIC ...

It also caps insulin costs at $35 per month for Medicare beneficiaries and a $2,000 out-of-pocket annual cap for people enrolled in a certain drug plan. Trump's reversal of the 2022 "Lowering ...

Science Immunology. 2024 saw the completion of several cellular-resolution brain maps, including the entire fly brain and a comprehensive connections map of a cubic centimeter of human brain. 2025 ...